This year, EANM is electing a new EANM Secretary/ Treasurer for the 2026–2027 term. Two highly qualified candidates are standing for election, but only one will be chosen by the EANM Members' Assembly. Make sure to read their interviews before casting your vote!



Meet **Pierre-Yves Salaun**(France)

1. Could you walk us through your journey into the nuclear medicine field?

I began my training in Nuclear Medicine in 2000 as a resident in Brest (France), after a short experience in Radiology. Drawn to its functional dimension, I joined the department led by Prof. Yves Bizais and later completed a fellowship with Steven Larson at the Memorial Sloan Kettering Cancer Center in New York City in 2003, which allowed me to gain early training in PET imaging. I became Assistant Professor in 2004, Associate Professor in 2007, and Full Professor in 2010. In 2006, I spent a year at the René Gauducheau Cancer Center in Nantes (France), under Prof. Françoise Bodéré, where I trained in targeted radionuclide therapy and completed my PhD on radioimmunotargeting of medullary thyroid carcinoma.

Since 2008, I have chaired the Department of Biophysics and Nuclear Medicine at the University of Brest, and since 2010, I have been the Head of the Departments of Nuclear Medicine and Targeted Radionuclide Therapy at Brest University Hospital. I have successfully trained and mentored numerous physician colleagues—five of whom are now full professors in the department—as well as radiopharmacists and medical physicists.

Clinically, after training in FDG-PET at MSKCC, I contributed to the introduction of PET imaging in Brest, oversaw the installation of one of the world's first Siemens Vision 600 digital PET/CT scanners in 2018, and the Vision Quadra whole-body PET/CT in 2023. Our department, now equipped with four SPECT/CT cameras, a dedicated CZT cardiac camera, and three digital PET/CT scanners, performs more than 10,000 scintigraphic procedures and 17,000 PET scans annually, and runs a fast-growing theranostic programme, strengthened by the advent of PSMA ligands. Beyond clinical work, I have served on the Medical Executive Board of Brest University Hospital, led digital transformation efforts, and co-chaired the IT governance committee.

Regarding education, I chaired the first-year medical curriculum jury at the Brest Faculty of Medicine for 10 years and coordinated the pilot of a new medical student selection system, which was later partially implemented nationwide. I was also Director of the Nuclear Medicine residency programme for Western France from 2011 to 2020.

My research is currently conducted within the GETBO laboratory (INSERM U1304). While my early work focused on oncology, particularly head and neck cancers, I later redirected my efforts toward venous thromboembolic disease (VTE), a quite neglected area in nuclear medicine but a priority in Brest. Through studies on the diagnosis of VTE—especially V/Q SPECT and PET—and the association between VTE and cancer, our team has become a national and international reference in pulmonary nuclear medicine. More recently, we launched a preclinical research programme developing novel PET tracers for venous thrombosis.

I have also actively contributed to our professional community for many years. I was a board member of the French College of Biophysics and Nuclear Medicine Professors (2010–2020), serving as Secretary General from 2017 to 2019. For the past 15 years, I have also served on the board of the French Society of Nuclear Medicine (SFMN), where I coordinated the National PET guidelines in oncology (certified by the French National Cancer Institute), later integrated into EANM guidelines. More recently, as President of the SFMN, I acted as liaison with health authorities on multiple issues (including regulatory texts, radiopharmaceutical shortages, radionuclide therapy development, international representation). I have also been actively involved with EANM since 2007 (see question 2).

2. Before running for a Board position, you have been involved with EANM. Could you share how you first became aware of EANM and the ways you have contributed to our community so far?

As a European nuclear medicine physician, I became an EANM member in 2007, recognising the importance of its mission for knowledge exchange. Since then, I have greatly valued participating in the EANM Annual Congresses and dedicated workshops.

I was able to work closely with colleagues who were actively involved in EANM, and hearing about their experiences was very inspiring and informative. I specifically collaborated with Patrick Bourguet, former EANM Secretary/Treasurer and EANM President, on guideline development, and with Roland Hustinx, former EANM Committee Coordinator, who entrusted me with the development of the EANM Clinical Decision Support platform. Building on this, I joined the working group led by Wolfgang Wadsak, former EANM Secretary/Treasurer, which resulted in the creation of the EANM Guidelines & Publications Council, of which I am currently a member.

In addition, I have acted as a liaison between EANM and the SFMN through my role as EANM National Delegate for France.



3. Serving on the EANM Board requires significant commitment. What motivated you to apply, and what inspired you to specifically seek the position of EANM Secretary/Treasurer?

I see the role of EANM Secretary/Treasurer as the natural next step in my journey with EANM. Having been involved with EANM over many years both as a National Delegate and as a member of the EANM Guidelines & Publications Council, I now would like to contribute at a more strategic level.

Thanks to my long-term involvement with EANM, I have developed a deep understanding of EANM's vision. My experience at both national and European levels has also allowed me to work on policy, education, digital transformation, and guideline harmonisation, which are areas that are central to EANM's mission.

The role of EANM Secretary/Treasurer requires trust, precision, and strong governance and financial expertise. Leading the Molecular Imaging and Radiotheranostics Department at Brest University Hospital, together with my service on institutional boards and governance committees (see question 1), has equipped me with solid experience in budget management, priority setting, and transparent reporting.

Lastly, I really look forward to working even more closely with my colleagues who are currently Board members, as well as the EANM Office, to make EANM and our field even more visible.

4. Beyond the Blouse: If you were not a nuclear medicine expert, what other career path would interest you?

If I had not become a physician, I believe I would have chosen to be an archaeologist, as I have always been passionate about history. However, retrospectively, I realise that the same motivations that led me to medicine—research and discovery—are also at the heart of archaeology. I might also have gone for a very different field, since I have always loved animals, especially horses, and particularly the discipline of classical dressage as taught in the Iberian schools. This passion is one of the other reasons I will enjoy visiting Vienna regularly if I am elected.